Welcome to our dedicated page for Structure Therapeutics American Depositary Shares news (Ticker: GPCR), a resource for investors and traders seeking the latest updates and insights on Structure Therapeutics American Depositary Shares stock.
Structure Therapeutics Inc. (NASDAQ: GPCR) is a clinical-stage biopharmaceutical company revolutionizing the treatment of chronic diseases through innovative oral therapeutics. The company’s lead product candidate, GSBR-1290, is an oral small molecule agonist targeting the glucagon-like-peptide-1 receptor (GLP-1R), a proven drug target for type-2 diabetes and obesity. By focusing on GPCRs, Structure Therapeutics aims to address significant unmet medical needs in metabolic and cardiopulmonary diseases.
In recent developments, Structure Therapeutics reported promising results from its Phase 1b study of GSBR-1290, showcasing its potential as a differentiated oral GLP-1 receptor agonist. The company is advancing GSBR-1290 into Phase 2 trials, aiming to further demonstrate its efficacy and safety in treating type-2 diabetes and obesity. Additionally, the company is developing other oral small-molecule therapeutics, including ANPA-0073 and LTSE-2578, targeting pulmonary and cardiovascular diseases.
Financially, Structure Therapeutics is in a robust position, with a cash reserve of $205.4 million as of September 30, 2023, and an additional $300 million raised through private placement in October 2023. This strong financial backing will support the advancement of the company’s clinical programs and achieve key milestones through 2026.
Structure Therapeutics' commitment to scientific innovation is evident in its next-generation structure-based drug discovery platform, which underpins its GPCR-targeted pipeline. The company’s strategic partnerships with leading healthcare investors further bolster its mission to deliver transformative oral therapies to patients worldwide.
For more information, visit www.structuretx.com.
Structure Therapeutics Inc. (NASDAQ: GPCR) reported its financial results for Q4 2022 and the full year ended December 31, 2022. The company completed its upsized IPO, raising approximately $185.3 million, with net proceeds of around $166.7 million. This funding bolsters its efforts to develop GSBR-1290, an oral GLP-1 agonist for type 2 diabetes and obesity. The Phase 1b study is now completed, and the firm anticipates topline data from the upcoming Phase 1b and Phase 2a studies in the second half of 2023. The net loss for 2022 was $51.3 million, a significant increase from $38.0 million in 2021, primarily due to heightened R&D expenses.
Structure Therapeutics Inc. (NASDAQ: GPCR) has successfully closed its upsized initial public offering (IPO) of 12,351,000 American depositary shares (ADSs) at a price of $15.00 per ADS, generating approximately $185.3 million before expenses. This offering included the full exercise of underwriters' options to purchase an additional 1,611,000 ADSs. The shares commenced trading on Nasdaq on February 3, 2023. Jefferies, SVB Securities, Guggenheim Securities, and BMO Capital Markets served as joint book-running managers for the offering. Structure Therapeutics focuses on developing novel oral small molecule therapeutics for metabolic and pulmonary diseases targeting the GPCR family.
Structure Therapeutics Inc. (NASDAQ: GPCR), backed by Qiming Venture Partners, successfully debuted on Nasdaq on February 3, 2023. Issued at $15.00 per ADS, it opened at $25.00, marking a 66.67% increase and a market cap of $915 million. Qiming Venture Partners has been an early investor since 2019. Structure Therapeutics focuses on converting biologics into orally available small molecules, targeting G-protein-coupled receptors. Their pipeline includes GSBR-1290 for type-2 diabetes and ANPA-0073 for pulmonary conditions, with significant studies completed in September 2022.
Structure Therapeutics Inc. (NASDAQ: GPCR) has successfully priced its upsized initial public offering (IPO) of 10,740,000 American depositary shares (ADSs) at $15.00 per ADS, anticipating gross proceeds of approximately $161.1 million. The offering includes a 30-day option for underwriters to purchase an additional 1,611,000 ADSs. Trading on the Nasdaq Global Market is set to begin on February 3, 2023, with completion expected by February 7, 2023. Structure Therapeutics focuses on developing novel oral therapeutics for metabolic and pulmonary diseases, leveraging a structure-based drug discovery platform.
FAQ
What is the current stock price of Structure Therapeutics American Depositary Shares (GPCR)?
What is the market cap of Structure Therapeutics American Depositary Shares (GPCR)?
What is Structure Therapeutics Inc.'s main focus?
What is GSBR-1290?
What recent financial achievements has Structure Therapeutics made?
What are the other therapeutic candidates in the pipeline?
How does Structure Therapeutics plan to use the proceeds from the recent financing?
What makes Structure Therapeutics' drug discovery platform unique?
Who are the key partners in the recent private placement financing?
What are the company's plans for GSBR-1290 in 2024?
How is Structure Therapeutics addressing the unmet medical needs?
Where can I find more information about Structure Therapeutics?
